{"id":68453,"date":"2026-06-17T22:46:48","date_gmt":"2026-06-17T14:46:48","guid":{"rendered":"https:\/\/flcube.com\/?p=68453"},"modified":"2026-06-17T22:46:49","modified_gmt":"2026-06-17T14:46:49","slug":"walvax-biotechnologys-13-valent-pneumococcal-vaccine-weuphoria-meets-all-endpoints-in-indonesian-phase-iii-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68453","title":{"rendered":"Walvax Biotechnology&#8217;s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Walvax Biotechnology Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300142:SHE\">SHE: 300142<\/a>) announced that its <strong>Phase III clinical study<\/strong> for <strong>Weuphoria<\/strong>, a <strong>13-valent pneumococcal conjugate vaccine (PCV13)<\/strong>, conducted in <strong>Indonesia<\/strong> has met <strong>all prespecified endpoints<\/strong>. The trial evaluated the vaccine under a <strong>&#8220;2p+1&#8221; immunization schedule<\/strong> (primary doses at 2 and 4 months, booster at 12\u201315 months) in healthy Indonesian infants, demonstrating robust immunogenicity and safety compared to an active control vaccine.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-milestone\" class=\"wp-block-heading\">Clinical Trial Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Walvax Biotechnology Co., Ltd (SHE: 300142)<\/td><\/tr><tr><td><strong>Vaccine Candidate<\/strong><\/td><td>Weuphoria \u2013 13-valent pneumococcal conjugate vaccine (PCV13)<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase III<\/td><\/tr><tr><td><strong>Geographic Location<\/strong><\/td><td>Indonesia<\/td><\/tr><tr><td><strong>Immunization Schedule<\/strong><\/td><td>&#8220;2p+1&#8221; (primary: 2 &amp; 4 months; booster: 12\u201315 months)<\/td><\/tr><tr><td><strong>Study Population<\/strong><\/td><td>Healthy Indonesian infants aged 6\u20138 weeks<\/td><\/tr><tr><td><strong>Trial Design<\/strong><\/td><td>Randomized, blinded, active-controlled<\/td><\/tr><tr><td><strong>Primary Endpoints<\/strong><\/td><td>All prespecified endpoints met (immunogenicity and safety)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-development-strategy\" class=\"wp-block-heading\">Product Profile &amp; Development Strategy<\/h2>\n\n\n\n<h3 id=\"h-weuphoria-vaccine-characteristics\" class=\"wp-block-heading\">Weuphoria Vaccine Characteristics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vaccine Type:<\/strong> 13-valent pneumococcal conjugate vaccine (PCV13)<\/li>\n\n\n\n<li><strong>Target Pathogen:<\/strong> Streptococcus pneumoniae serotypes responsible for invasive pneumococcal disease<\/li>\n\n\n\n<li><strong>Immunization Schedule:<\/strong> &#8220;2p+1&#8221; regimen aligned with WHO recommendations and local EPI requirements<\/li>\n\n\n\n<li><strong>Co-administration Capability:<\/strong> Successfully evaluated alongside routine infant vaccines in Indonesia&#8217;s Expanded Programme on Immunization (EPI)<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-trial-design-features\" class=\"wp-block-heading\">Clinical Trial Design Features<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Active Control:<\/strong> Compared against established PCV13 reference vaccine<\/li>\n\n\n\n<li><strong>Real-World Relevance:<\/strong> Conducted in target population within local immunization infrastructure<\/li>\n\n\n\n<li><strong>Comprehensive Assessment:<\/strong> Evaluated both immunogenicity and safety endpoints<\/li>\n\n\n\n<li><strong>Program Integration:<\/strong> Demonstrated compatibility with existing EPI vaccine schedule<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indonesian Market Opportunity:<\/strong> Indonesia represents one of Southeast Asia&#8217;s largest pediatric vaccine markets with significant unmet need for pneumococcal protection<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Successful Phase III data supports marketing authorization application in Indonesia<\/li>\n\n\n\n<li><strong>Global Expansion Potential:<\/strong> Indonesia approval may facilitate regulatory filings in other ASEAN countries<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Positions Walvax as credible alternative to established multinational PCV13 manufacturers<\/li>\n\n\n\n<li><strong>Public Health Impact:<\/strong> Addresses critical gap in pneumococcal disease prevention in high-burden developing market<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-commercial-advantages\" class=\"wp-block-heading\">Strategic Commercial Advantages<\/h2>\n\n\n\n<h3 id=\"h-local-market-integration\" class=\"wp-block-heading\">Local Market Integration<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>EPI Compatibility:<\/strong> Successful co-administration with routine vaccines ensures seamless integration into national immunization programs<\/li>\n\n\n\n<li><strong>Schedule Alignment:<\/strong> &#8220;2p+1&#8221; regimen matches existing infrastructure and healthcare provider practices<\/li>\n\n\n\n<li><strong>Cost-Effectiveness:<\/strong> Potential pricing advantage over imported PCV13 vaccines in price-sensitive markets<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-global-platform-potential\" class=\"wp-block-heading\">Global Platform Potential<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing Scale:<\/strong> Successful development validates Walvax&#8217;s conjugate vaccine manufacturing capabilities<\/li>\n\n\n\n<li><strong>Technology Transfer:<\/strong> Platform technology applicable to other conjugate vaccine development<\/li>\n\n\n\n<li><strong>Partnership Opportunities:<\/strong> Strong clinical data may attract international distribution partnerships<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-outlook\" class=\"wp-block-heading\">Strategic Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The successful completion of the Indonesian Phase III trial represents a significant milestone in Walvax&#8217;s international expansion strategy, transforming Weuphoria from a domestic candidate to a globally viable PCV13 vaccine. The comprehensive endpoint achievement under real-world EPI conditions demonstrates both clinical efficacy and practical implementability, addressing two critical requirements for public health adoption. This success not only opens the substantial Indonesian market but also establishes a regulatory precedent for potential approvals across Southeast Asia and other developing regions where pneumococcal disease burden remains high and vaccine access is limited.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market access, and commercial performance. Actual results may differ due to regulatory decisions, competitive dynamics, pricing negotiations, and public health procurement processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u6c83\u68ee\u751f\u7269\uff1a\u5173\u4e8e13\u4ef7\u80ba\u708e\u7403\u83cc\u591a\u7cd6\u7ed3\u5408\u75ab\u82d7\u5370\u5ea6\u5c3c\u897f\u4e9a2p1\u514d\u75ab\u7a0b\u5e8f\u2162\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u62a5\u544a\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u6c83\u68ee\u751f\u7269\uff1a\u5173\u4e8e13\u4ef7\u80ba\u708e\u7403\u83cc\u591a\u7cd6\u7ed3\u5408\u75ab\u82d7\u5370\u5ea6\u5c3c\u897f\u4e9a2p+1\u514d\u75ab\u7a0b\u5e8f\u2162\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u62a5\u544a\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-9ba44ca3-879a-4439-9a60-e078ea201300\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u6c83\u68ee\u751f\u7269\uff1a\u5173\u4e8e13\u4ef7\u80ba\u708e\u7403\u83cc\u591a\u7cd6\u7ed3\u5408\u75ab\u82d7\u5370\u5ea6\u5c3c\u897f\u4e9a2p1\u514d\u75ab\u7a0b\u5e8f\u2162\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u62a5\u544a\u7684\u516c\u544a.pdf\">\u6c83\u68ee\u751f\u7269\uff1a\u5173\u4e8e13\u4ef7\u80ba\u708e\u7403\u83cc\u591a\u7cd6\u7ed3\u5408\u75ab\u82d7\u5370\u5ea6\u5c3c\u897f\u4e9a2p+1\u514d\u75ab\u7a0b\u5e8f\u2162\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u62a5\u544a\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/\u6c83\u68ee\u751f\u7269\uff1a\u5173\u4e8e13\u4ef7\u80ba\u708e\u7403\u83cc\u591a\u7cd6\u7ed3\u5408\u75ab\u82d7\u5370\u5ea6\u5c3c\u897f\u4e9a2p1\u514d\u75ab\u7a0b\u5e8f\u2162\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u62a5\u544a\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9ba44ca3-879a-4439-9a60-e078ea201300\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Walvax Biotechnology Co., Ltd (SHE: 300142) announced that its Phase III clinical study for Weuphoria,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[17,1152,12,332],"class_list":["post-68453","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-she-300142","tag-vaccine","tag-walvax-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Walvax Biotechnology&#039;s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Walvax Biotechnology Co., Ltd (SHE: 300142) announced that its Phase III clinical study for Weuphoria, a 13-valent pneumococcal conjugate vaccine (PCV13), conducted in Indonesia has met all prespecified endpoints. The trial evaluated the vaccine under a &quot;2p+1&quot; immunization schedule (primary doses at 2 and 4 months, booster at 12\u201315 months) in healthy Indonesian infants, demonstrating robust immunogenicity and safety compared to an active control vaccine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68453\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Walvax Biotechnology&#039;s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial\" \/>\n<meta property=\"og:description\" content=\"Walvax Biotechnology Co., Ltd (SHE: 300142) announced that its Phase III clinical study for Weuphoria, a 13-valent pneumococcal conjugate vaccine (PCV13), conducted in Indonesia has met all prespecified endpoints. The trial evaluated the vaccine under a &quot;2p+1&quot; immunization schedule (primary doses at 2 and 4 months, booster at 12\u201315 months) in healthy Indonesian infants, demonstrating robust immunogenicity and safety compared to an active control vaccine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68453\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-17T14:46:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-17T14:46:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68453#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68453\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Walvax Biotechnology&#8217;s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial\",\"datePublished\":\"2026-06-17T14:46:48+00:00\",\"dateModified\":\"2026-06-17T14:46:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68453\"},\"wordCount\":507,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"SHE: 300142\",\"Vaccine\",\"Walvax Biotechnology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68453#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68453\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68453\",\"name\":\"Walvax Biotechnology's 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-17T14:46:48+00:00\",\"dateModified\":\"2026-06-17T14:46:49+00:00\",\"description\":\"Walvax Biotechnology Co., Ltd (SHE: 300142) announced that its Phase III clinical study for Weuphoria, a 13-valent pneumococcal conjugate vaccine (PCV13), conducted in Indonesia has met all prespecified endpoints. The trial evaluated the vaccine under a \\\"2p+1\\\" immunization schedule (primary doses at 2 and 4 months, booster at 12\u201315 months) in healthy Indonesian infants, demonstrating robust immunogenicity and safety compared to an active control vaccine.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68453#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68453\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68453#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Walvax Biotechnology&#8217;s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Walvax Biotechnology's 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Walvax Biotechnology Co., Ltd (SHE: 300142) announced that its Phase III clinical study for Weuphoria, a 13-valent pneumococcal conjugate vaccine (PCV13), conducted in Indonesia has met all prespecified endpoints. The trial evaluated the vaccine under a \"2p+1\" immunization schedule (primary doses at 2 and 4 months, booster at 12\u201315 months) in healthy Indonesian infants, demonstrating robust immunogenicity and safety compared to an active control vaccine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68453","og_locale":"en_US","og_type":"article","og_title":"Walvax Biotechnology's 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial","og_description":"Walvax Biotechnology Co., Ltd (SHE: 300142) announced that its Phase III clinical study for Weuphoria, a 13-valent pneumococcal conjugate vaccine (PCV13), conducted in Indonesia has met all prespecified endpoints. The trial evaluated the vaccine under a \"2p+1\" immunization schedule (primary doses at 2 and 4 months, booster at 12\u201315 months) in healthy Indonesian infants, demonstrating robust immunogenicity and safety compared to an active control vaccine.","og_url":"https:\/\/flcube.com\/?p=68453","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-17T14:46:48+00:00","article_modified_time":"2026-06-17T14:46:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68453#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68453"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Walvax Biotechnology&#8217;s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial","datePublished":"2026-06-17T14:46:48+00:00","dateModified":"2026-06-17T14:46:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68453"},"wordCount":507,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","SHE: 300142","Vaccine","Walvax Biotechnology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68453#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68453","url":"https:\/\/flcube.com\/?p=68453","name":"Walvax Biotechnology's 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-17T14:46:48+00:00","dateModified":"2026-06-17T14:46:49+00:00","description":"Walvax Biotechnology Co., Ltd (SHE: 300142) announced that its Phase III clinical study for Weuphoria, a 13-valent pneumococcal conjugate vaccine (PCV13), conducted in Indonesia has met all prespecified endpoints. The trial evaluated the vaccine under a \"2p+1\" immunization schedule (primary doses at 2 and 4 months, booster at 12\u201315 months) in healthy Indonesian infants, demonstrating robust immunogenicity and safety compared to an active control vaccine.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68453#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68453"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68453#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Walvax Biotechnology&#8217;s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68453"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68453\/revisions"}],"predecessor-version":[{"id":68455,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68453\/revisions\/68455"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}